Table 1 Donor and recipient characteristics with Log-rank test p-value for qualitative variables and quantitative variables across risk groups when significant threshold was met.
From: A Donor Quality Index for liver transplantation: development, internal and external validation
Donor characteristics | Mean survival (sd) | P-value | |
|---|---|---|---|
Sex (%): | 0.37 | ||
Male | 55.01 | 4.55 (0.05) | |
Female | 44.99 | 4.56 (0.08) | |
Cause of death (%): | <0.01 | ||
Cerebrovascular accident | 60.29 | 4.44 (0.05) | |
Trauma | 24.64 | 4.69 (0.07) | |
Anoxia | 12.02 | 4.80 (0.11) | |
Other | 3.05 | 4.72 (0.21) | |
Diabetes (%): | 0.98 | ||
yes | 7.75 | 4.56 (0.14) | |
no | 92.25 | 4.56 (0.04) | |
ABO group (%): | 0.22 | ||
A | 44.58 | 4.57 (0.06) | |
B | 9.87 | 4.72 (0.12) | |
O | 41.93 | 4.49 (0.06) | |
AB | 3.61 | 4.78 (0.19) | |
Hypertension (%): | 0.21 | ||
yes | 35.70 | 4.49 (0.07) | |
no | 64.30 | 4.60 (0.05) | |
Malignancy (%): | 0.43 | ||
yes | 1.89 | 4.72 (0.26) | |
no | 98.11 | 4.49 (0.04) | |
Alcohol (%): | 0.53 | ||
yes | 15.02 | 4.50 (0.10) | |
no | 84.98 | 4.57 (0.04) | |
Smoking (%): | 0.47 | ||
yes | 37.59 | 4.59 (0.06) | |
no | 62.41 | 4.53 (0.05) | |
Drugs (%): | 0.52 | ||
yes | 4.17 | 4.65 (0.19) | |
no | 95.83 | 4.56 (0.04) | |
Hepatitis C virus antibody (%): | 0.46 | ||
+ | 0.45 | 4.09 (0.56) | |
− | 99.55 | 4.53 (0.04) | |
Hepatitis B core antibody (%): | 0.62 | ||
+ | 4.39 | 4.61 (0.18) | |
− | 95.61 | 4.53 (0.04) | |
Inotropes (dobutamine, dopamine, noradrenaline, epinephrine) (%): | 0.72 | ||
yes | 39.16 | 4.57 (0.06) | |
no | 60.84 | 4.55 (0.05) | |
Liver type (%): | 0.44 | ||
Partial/split | 5.10 | 4.43 (0.17) | |
Total | 94.90 | 4.55 (0.04) | |
Age (%): | <0.001 | ||
≤69 | 76.47 | 4.64 (0.04) | |
>69 | 23.53 | 4.27 (0.09) | |
Height (%): | 0.07 | ||
<162 | 22.62 | 4.42 (0.08) | |
≥162 | 77.38 | 4.60 (0.04) | |
Weight, mean (sd) | 72.88 (15.17) | ||
BMI, mean (sd) | 25.33 (4.62) | ||
Sodium: latest (mmol/L) (%): | 0.04 | ||
136–146 | 43.85 | 4.47(0.06) | |
other | 56.15 | 4.63(0.05) | |
Sodium: highest (mmol/L), median (range) | 149 (120–180) | ||
MDRD creatinine clearance: latest (ml/min/1.73 m2) (%): | 0.01 | ||
<60 | 25.30 | 4.38 (50.08) | |
60–89 | 29.51 | 4.55 (0.07) | |
≥90 | 45.19 | 4.66 (0.06) | |
MDRD creatinine clearance: lowest (ml/min/1.73 m2) (%): | 0.01 | ||
<60 | 35.35 | 4.41 (0.07) | |
60–89 | 36.83 | 4.61 (0.06) | |
≥90 | 27.82 | 4.68 (0.07) | |
Aspartate aminotransferase: latest (U/L), median (range) | 39 (0–2000) | ||
Aspartate aminotransferase: highest (U/L), median (range) | 51 (9–2000) | ||
Alanine transaminase: latest (U/L) (%): | 0.04 | ||
7–41 | 67.33 | 4.50 (0.05) | |
other | 32.67 | 4.67 (0.07) | |
Alanine transaminase: highest (U/L), median (range) | 33 (1–2000) | ||
Total bilirubin: latest (µmol/L), median (range) | 10 (0–150) | ||
Total bilirubin: highest (µmol/L), median (range) | 12 (1–150) | ||
Alkaline phosphatases: latest (U/L) (%): | 0.06 | ||
<33 | 4.44 | 4.26 (0.19) | |
33–96 | 76.12 | 4.54 (0.04) | |
>96 | 19.44 | 4.71 (0.08) | |
Alkaline phosphatases: highest (U/L) (%): | 0.09 | ||
<33 | 1.78 | 4.22 (0.31) | |
33–96 | 72.22 | 4.51 (0.05) | |
>96 | 26.00 | 4.67 (0.07) | |
Gamma glutamyl transpeptidase: latest (U/L), median (range) | 30 (0–1477) | ||
Gamma glutamyl transpeptidase: highest (U/L), median (range) | 36 (1–1835) | ||
Intensive care unit stay (in days) (%): | <0.001 | ||
≤4 | 79.68 | 4.48 (0.04) | |
>4 | 29.32 | 4.83 (0.08) | |
Estimated distance between donor and recipient location (minutes) (%): | <0.01 | ||
<15 | 22.60 | 4.77 (0.08) | |
≥15 | 77.40 | 4.50 (0.04) | |
“Hors tour” (%): | 0.84 | ||
yes | 6.08 | 4.57 (0.16) | |
no | 93.92 | 4.55 (0.04) | |
Donor risk index, mean (sd) | 1.65 (0.40) | — | — |
Eurotransplant donor risk index, mean (sd) | 1.63 (0.36) | — | — |
UK Donor Liver Index, mean (sd) | 1.15 (0.26) | — | — |
Recipient characteristics | Mean survival (sd) | P-value | |
Sex (%): | 0.91 | ||
Male | 73.54 | 4.55 (0.05) | |
Female | 26.46 | 4.56 (0.08) | |
Cancer (%): | 0.29 | ||
yes | 29.00 | 4.62 (0.07) | |
no | 71.00 | 4.53 (0.05) | |
Decompensated cirrhosis (%): | <0.001 | ||
yes | 37.74 | 4.73 (0.06) | |
no | 62.26 | 4.46 (0.05) | |
Non-cirrhotic liver disease (%): | 0.63 | ||
yes | 1.41 | 4.63 (0.30) | |
no | 98.59 | 4.48 (0.04) | |
Emergency (%): | <0.001 | ||
yes | 6.72 | 3.78 (0.17) | |
no | 93.28 | 4.58 (0.04) | |
MELD exception (%): | 0.36 | ||
yes | 18.00 | 4.45 (0.09) | |
no | 82.00 | 4.57 (0.04) | |
Previous transplantation (%): | <0.001 | ||
yes | 8.58 | 3.76 (0.15) | |
no | 91.42 | 4.60 (0.04) | |
On dialysis (%): | <0.001 | ||
yes | 5.33 | 3.43 (0.19) | |
no | 94.67 | 4.58 (0.04) | |
Medical condition before LT (%): | <0.001 | ||
Intensive care unit | 17.70 | 3.88 (0.11) | |
Hospital (no intensive care unit) | 13.88 | 4.60 (0.10) | |
Not hospitalized | 68.42 | 4.71 (0.04) | |
Hepatitis B core antibody (%): | 0.73 | ||
+ | 20.05 | 4.53 (0.09) | |
− | 79.95 | 4.56 (0.04) | |
Hepatitis C virus antibody (%): | <0.001 | ||
+ | 23.83 | 4.23 (0.08) | |
− | 76.17 | 4.66 (0.04) | |
Diabetes (%): | 0.06 | ||
yes | 22.67 | 4.42 (0.08) | |
no | 77.33 | 4.60 (0.04) | |
Encephalopathy (%): | <0.001 | ||
grade 1 | 68.14 | 4.62 (0.05) | |
grade 2 | 24.84 | 4.52 (0.08) | |
grade 3 | 7.02 | 3.95 (0.17) | |
ABO group (%): | 0.80 | ||
A | 45.44 | 4.56 (0.06) | |
B | 11.16 | 4.63 (0.11) | |
O | 39.03 | 4.55 (0.06) | |
AB | 4.37 | 4.43 (0.19) | |
Age, mean (sd) | 53.24 (10.39) | ||
Body mass index (%): | 0.20 | ||
<18.5 | 3.56 | 4.35 (0.21) | |
18.5–25 | 44.69 | 4.50 (0.06) | |
≥25 | 51.75 | 4.62 (0.05) | |
Model for end stage liver disease before LT (%): | <0.001 | ||
<29 | 72.73 | 4.65 (0.04) | |
≥29 | 27.27 | 4.32 (0.08) | |
Waiting time (in days) (%): | <0.001 | ||
<21 | 24.54 | 4.34 (0.08) | |
≥21 | 75.46 | 4.63 (0.04) | |
Follow-up (years), mean (sd) | 2.33 (1.63) |
